MT 102 - Myeloid Therapeutics
Alternative Names: MT-102 - Myeloid TherapeuticsLatest Information Update: 13 Jul 2023
At a glance
- Originator Myeloid Therapeutics
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Cell replacements; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours